Presented by Coalition to Strengthen America’s Healthcare{beacon} Health Care Health Care The Big Story Moderna’s mRNA flu shot to get FDA review After some initial ...
Welcome to another installment of This Week at FDA, your weekly source for updates – big and small – on FDA, drug and medical ...
After getting slapped with a surprise refuse-to-file letter signed by former CBER Director Vinay Prasad, Moderna’s flu ...
Investigators in New Mexico are trying to identify a mysterious substance that may have contributed to the deaths of three ...
StockStory.org on MSN
3 cash-burning stocks with open questions
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to ...
Moderna (NASDAQ:MRNA) is back in the headlines after ripping 63.17% higher year to date on a surprise Q1 revenue triple and ...
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...
Regulatory Recon is our regular intelligence briefing for the regulatory affairs space, bringing you the top regulatory, ...
The U.S. FDA said on Thursday it would hold a meeting of outside experts next month to review Moderna's experimental flu shot.
Moderna Inc.’s experimental flu shot made with mRNA technology will be reviewed by a Food and Drug Administration advisory ...
CEO Matthew Gline said the quarter included “the preliminary open-label period data from the 1402 study in D2T RA” and a “planned spotlight… on mosliciguat,” alongside “some smaller updates on the ...
A decade after Ebola vaccines changed outbreak response, a new epidemic in central Africa is caused by a strain the world ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results